SMN1 and neoplasm: Consistent with the prior results, SU.86.86 tumors had significantly more CD31 (p<0.05) staining than either Hs766t or MIA PaCa-2 (Fig. 3A–B), and significantly more SMA (p<0.005) than MIA PaCa-2 tumor samples (Fig. 3A, C).